Clinical Trial Update: Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluating donafenib in iodine-131 refractory differentiated thyroid cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Donafenib (donafenib)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Differentiated Thyroid Cancer | Phase 2 | Status: COMPLETED